Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol
Sagnik Bhattacharyya, Paolo Fusar‐poli, Stefan Borgwardt, Rocío Martín‐Santos, Chiara Nosarti, C. O’Carroll, Paul Allen, Marc L. Seal, Paul C. Fletcher, José A. Crippa, Vincent Giampietro, Andrea Mechelli, Zerrin Atakan, Philip Mcguire
Archives of General Psychiatry April 1, 2009 DOI: 10.1001/archgenpsychiatry.2009.17 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Placebo-controlled Double-blind Peer reviewed |
|---|---|
| Sample size | 15 |
| Population | Healthy, native English-speaking, right-handed men of white race/ethnicity who had used cannabis 15 times or less and had minimal exposure to other illicit drugs |
| Interventions | Delta9-tetrahydrocannabinol Cannabidiol Placebo |
| Dose | 10 mg Delta9-THC, 600 mg cannabidiol |
| Duration | Single-dose sessions with no specified follow-up |
| Topics | Anxiety Cannabis CBD |
| Keywords | Sedation Verbal learning Placebo Audiology Psychosis Schizophrenia object-oriented programming Cognition Anesthesia Cannabinoid |
| Citations | 250 |
| Key findings | Delta9-THC increased psychotic symptoms and altered parahippocampal and ventrostriatal brain activation during verbal learning, while cannabidiol had no significant effects. |
Abstract
CONTEXT: Cannabis sativa use can impair verbal learning, provoke acute psychosis, and increase the risk of schizophrenia. It is unclear where C. sativa acts in the human brain to modulate verbal learning and to induce psychotic symptoms.
Objectives: To investigate the effects of 2 main psychoactive constituents of C. sativa, Delta9-tetrahydrocannabinol (Delta9-THC) and cannabidiol, on regional brain function during verbal paired associate learning.
Design: Subjects were studied on 3 separate occasions using a block design functional magnetic resonance imaging paradigm while performing a verbal paired associate learning task. Each imaging session was preceded by the ingestion of Delta9-THC (10 mg), cannabidiol (600 mg), or placebo in a double-blind, randomized, placebo-controlled, repeated-measures, within-subject design.
Setting: University research center.
Participants: Fifteen healthy, native English-speaking, right-handed men of white race/ethnicity who had used C. sativa 15 times or less and had minimal exposure to other illicit drugs in their lifetime. MAIN OUTCOME MEASURES: Regional brain activation (blood oxygen level-dependent response), performance in a verbal learning task, and objective and subjective ratings of psychotic symptoms, anxiety, intoxication, and sedation.
Results: Delta9-Tetrahydrocannabinol increased psychotic symptoms and levels of anxiety, intoxication, and sedation, whereas no significant effect was noted on these parameters following administration of cannabidiol. Performance in the verbal learning task was not significantly modulated by either drug. Administration of Delta9-THC augmented activation in the parahippocampal gyrus during blocks 2 and 3 such that the normal linear decrement in activation across repeated encoding blocks was no longer evident. Delta9-Tetrahydrocannabinol also attenuated the normal time-dependent change in ventrostriatal activation during retrieval of word pairs, which was directly correlated with concurrently induced psychotic symptoms. In contrast, administration of cannabidiol had no such effect.
Conclusion: The modulation of mediotemporal and ventrostriatal function by Delta9-THC may underlie the effects of C. sativa on verbal learning and psychotic symptoms, respectively.
In the evidence
This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.
-
THC increased anxiety, intoxication, sedation and psychotic symptoms, whereas CBD had no significant effect on these measures.
Synthesized
-
State of the evidence: CBD No effect
THC increased psychotic symptoms, anxiety, intoxication, and sedation and altered brain activation during verbal learning, whereas CBD had no significant effects on these measures.
Synthesized
Comparable studies
Other randomized controlled trials on cannabis for anxiety, most cited first.
Citations in the library
Cited by 63
- The neuropsychopharmacology of cannabis: A review of human imaging studies Pharmacology & Therapeutics October 20, 2018
- Human Laboratory Studies on Cannabinoids and Psychosis. Biological Psychiatry April 1, 2016
- Substance-Induced Psychoses: An Updated Literature Review Frontiers in Psychiatry December 23, 2021
- Effects of Cannabis on Impulsivity: A Systematic Review of Neuroimaging Findings Current Pharmaceutical Design May 10, 2014
- Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain Frontiers in Pharmacology 2014
and 58 more in the library
Cites 6
- Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug Brazilian Journal of Medical and Biological Research April 1, 2006
- Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids Behavioural Pharmacology September 1, 2005
- Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. Brain research. Cognitive brain research April 2005
- Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage November 2004
- The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology August 2004
and 1 more in the library